C.

Serial Number 97979331
Registration 7725052
700

Registration Progress

Application Filed
Mar 7, 2022
Under Examination
Mar 21, 2023
Approved for Publication
Jan 24, 2023
Published for Opposition
Jan 24, 2023
Registered
Mar 11, 2025

Basic Information

Serial Number
97979331
Registration Number
7725052
Filing Date
March 7, 2022
Registration Date
March 11, 2025
Published for Opposition
January 24, 2023
Drawing Code
3

Status Summary

Current Status
Active
Status Code
700
Status Date
Mar 11, 2025
Registration
Registered
Classes
005 042

Rights Holder

Cytokinetics, Incorporated

03
Address
350 Oyster Point Blvd
South San Francisco, CA 94080

Ownership History

Cytokinetics, Incorporated

Original Applicant
03
South San Francisco, CA

Cytokinetics, Incorporated

Owner at Publication
03
South San Francisco, CA

Cytokinetics, Incorporated

Original Registrant
03
South San Francisco, CA

Legal Representation

Attorney
B. Brett Heavner

USPTO Deadlines

Next Renewal Deadline
2073 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2025-03-11)
Due Date
March 11, 2031
Grace Period Ends
September 11, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

39 events
Date Code Type Description
Mar 11, 2025 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED
Mar 11, 2025 R.PR A REGISTERED-PRINCIPAL REGISTER
Feb 20, 2025 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 20, 2025 ALIE A ASSIGNED TO LIE
Feb 20, 2025 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Feb 20, 2025 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 20, 2025 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Feb 12, 2025 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 23, 2024 CNRT W SU - NON-FINAL ACTION - WRITTEN
Nov 23, 2024 GNRT O NON-FINAL ACTION E-MAILED
Nov 23, 2024 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED
Nov 22, 2024 SUPC I STATEMENT OF USE PROCESSING COMPLETE
Nov 22, 2024 DPCC D DIVISIONAL PROCESSING COMPLETE
Oct 24, 2024 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL
Aug 20, 2024 ERTD I TEAS REQUEST TO DIVIDE RECEIVED
Aug 20, 2024 EXT3 S SOU EXTENSION 3 FILED
Aug 20, 2024 EX3G S SOU EXTENSION 3 GRANTED
Aug 20, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 20, 2024 EISU I TEAS STATEMENT OF USE RECEIVED
Aug 20, 2024 EEXT I SOU TEAS EXTENSION RECEIVED
Aug 20, 2024 IUAF S USE AMENDMENT FILED
Aug 20, 2024 DRRR I DIVISIONAL REQUEST RECEIVED
Mar 13, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 12, 2024 EXT2 S SOU EXTENSION 2 FILED
Mar 12, 2024 EEXT I SOU TEAS EXTENSION RECEIVED
Mar 12, 2024 EX2G S SOU EXTENSION 2 GRANTED
Sep 9, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 7, 2023 EX1G S SOU EXTENSION 1 GRANTED
Sep 7, 2023 EXT1 S SOU EXTENSION 1 FILED
Sep 7, 2023 EEXT I SOU TEAS EXTENSION RECEIVED
Mar 21, 2023 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jan 24, 2023 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 24, 2023 PUBO A PUBLISHED FOR OPPOSITION
Jan 4, 2023 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 19, 2022 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 17, 2022 DOCK D ASSIGNED TO EXAMINER
Mar 12, 2022 MDSC E NOTICE OF DESIGN SEARCH CODE E-MAILED
Mar 11, 2022 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 10, 2022 NWAP I NEW APPLICATION ENTERED

Detailed Classifications

Class 005
human pharmaceuticals for the treatment of cardiovascular diseases, diseases and conditions associated with cardiac muscle dysfunction, cardiac muscle wasting, cardiac muscle atrophy, cardiac muscle weakness
First Use Anywhere: Jun 5, 2023
First Use in Commerce: Jun 5, 2023
Class 042
research in the field of cellular assay screening and pharmaceutical discovery and development
First Use Anywhere: 20150900
First Use in Commerce: 20150900

Additional Information

Design Mark
The mark consists of stylized "C" with a circle between the opening.
Color Claim
Color is not claimed as a feature of the mark.

Classification

International Classes
005 042